For instance, anti PD-1/PD-L1 mAbs plus anti-angiogenic agents, such as bevacizumab, has been associated with improved clinical outcomes in HCC patients (24–26), and combination chemotherapy with ICIs has shown potential as first-line treatment for advanced ICC (27). The gene discussed is CD274; the disease is intrahepatic cholangiocarcinoma.